• Inhalation Research Services
    • Efficacy studies/ Disease models
    • Formulation
    • PK studies
      • Aerosol characterization
      • In vivo PK studies
      • Ex vivo Isolated Perfused Lung method
      • In vitro dissolution tests – DissolvIt
      • In vitro cell permeability tests
    • Toxicology studies
    • Combination product development/ Device selection/ CMC data
  • Instruments
    • PreciseInhale®
      • Precision dosing
      • PreciseInhale® input: Inhaler
      • PreciseInhale® input: Nebulizer
      • White paper
    • DissolvIt ®
    • XposeALI ®
    • Nose-Only
    • Intratracheal
    • Technical specifications
  • Publications
  • Webinars
  • About
    • About Us
    • Our Customers
    • Our Team
    • Management
    • Board
    • Advisory Board
  • Investors / investerare
    • Bolagsanalys
    • Pressmeddelanden
    • Prenumerera
    • IPO 2017
    • Finansiering 2025
    • Finansiella rapporter
    • Kalender
    • Ägarlista
    • Bolagstämma
    • Bolagsstyrning
    • Presentationer
  • Contact
Inhalation
  • Inhalation Research Services
    • Efficacy studies/ Disease models
    • Formulation
    • PK studies
      • Aerosol characterization
      • In vivo PK studies
      • Ex vivo Isolated Perfused Lung method
      • In vitro dissolution tests – DissolvIt
      • In vitro cell permeability tests
    • Toxicology studies
    • Combination product development/ Device selection/ CMC data
  • Instruments
    • PreciseInhale®
      • Precision dosing
      • PreciseInhale® input: Inhaler
      • PreciseInhale® input: Nebulizer
      • White paper
    • DissolvIt ®
    • XposeALI ®
    • Nose-Only
    • Intratracheal
    • Technical specifications
  • Publications
  • Webinars
  • About
    • About Us
    • Our Customers
    • Our Team
    • Management
    • Board
    • Advisory Board
  • Investors / investerare
    • Bolagsanalys
    • Pressmeddelanden
    • Prenumerera
    • IPO 2017
    • Finansiering 2025
    • Finansiella rapporter
    • Kalender
    • Ägarlista
    • Bolagstämma
    • Bolagsstyrning
    • Presentationer
  • Contact
  • Bolagsanalys
  • Pressmeddelanden
  • Prenumerera
  • IPO 2017
  • Finansiering 2025
  • Finansiella rapporter
  • Kalender
  • Ägarlista
  • Bolagstämma
  • Bolagsstyrning
  • Presentationer

Prenumerera

Language


Information type




Contact

Hälsovägen 7
Novum Floor 6, Elevator E
141 57 Huddinge, Sweden.
contact@inhalation.se
+46 (0) 705 625 195

Visitor entrance: Blickagången 6, Floor 6, Elevator E

Useful links
  • Inhalation Research Services
    • Efficacy studies/ Disease models
    • Formulation
    • PK studies
      • Aerosol characterization
      • In vivo PK studies
      • Ex vivo Isolated Perfused Lung method
      • In vitro dissolution tests – DissolvIt
      • In vitro cell permeability tests
    • Toxicology studies
    • Combination product development/ Device selection/ CMC data
  • Instruments
    • PreciseInhale®
      • Precision dosing
      • PreciseInhale® input: Inhaler
      • PreciseInhale® input: Nebulizer
      • White paper
    • DissolvIt ®
    • XposeALI ®
    • Nose-Only
    • Intratracheal
    • Technical specifications
  • Publications
  • Webinars
  • About
    • About Us
    • Our Customers
    • Our Team
    • Management
    • Board
    • Advisory Board
  • Investors / investerare
    • Bolagsanalys
    • Pressmeddelanden
    • Prenumerera
    • IPO 2017
    • Finansiering 2025
    • Finansiella rapporter
    • Kalender
    • Ägarlista
    • Bolagstämma
    • Bolagsstyrning
    • Presentationer
  • Contact
About Us

Inhalation Sciences is a cutting-edge Contract Research Organization (CRO) specializing in inhalation drug development. Leveraging our proprietary technology platform, PreciseInhale®, we empower our clients to de-risk and accelerate their R&D pipelines by delivering high-resolution, predictive data early in the development process.

Privacy policy

Copyright © 2025 Inhalation. All rights reserved.

Design mkmedia
Contact us!
To top